• Modular Medical posted a net loss of $28.24 million, widening from $18.82 million a year earlier.
• Operating loss widened to $27.56 million as operating expenses climbed to $27.56 million, led by R&D spending of $19.97 million.
• Cash and cash equivalents fell to $6.94 million at March 31, 2026 from $13.1 million a year earlier.
• The company received FDA clearance for Pivot in April 2026, began initial U.S. shipments in June 2026, and expects CE mark clearance by Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073223), on June 29, 2026, and is solely responsible for the information contained therein.